Research Topics
Species | Jorge A MarreroSummaryAffiliation: University of Michigan Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United StatesJorge A Marrero
Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
Hepatology 36:1349-54. 2002..Because of the increasing incidence of NAFLD, further studies are needed to determine the risk of HCC in patients with NAFLD...- Staging systems for hepatocellular carcinoma: should we all use the BCLC system?Jorge A Marrero
J Hepatol 44:630-2. 2006 
The challenge of prognosis and staging for hepatocellular carcinomaJorge A Marrero
Multidisciplinary Liver Tumor Program, University of Michigan, Ann Arbor, Michigan 48109, USA
Oncologist 15:23-33. 2010..Although more work is required, it is hoped that these and other ongoing research efforts will eventually enable the development of a global staging classification...- Modern diagnosis and management of hepatocellular carcinomaJorge A Marrero
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
Clin Liver Dis 13:233-47. 2009..Resection, transplantation, and percutaneous ablation are considered curative interventions and are currently applied to about 30% of all patients with HCC... 
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinomaJorge A Marrero
University of Michigan, Ann Arbor, Michigan 48109, USA
Gastroenterology 137:110-8. 2009..The aims of this study were to determine performance of DCP and AFP-L3% for the diagnosis of early HCC; whether they complement AFP; and what factors affect DCP, AFP-L3%, or AFP levels...- Hepatocellular carcinomaJorge A Marrero
Division of Gastroenterology, Department of Internal Medicine, 3912 Taubman Center, University of Michigan, Ann Arbor, MI 48109, USA
Clin Liver Dis 10:339-51, ix. 2006..Resection, transplantation, and percutaneous ablation are considered curative interventions and are applied to about 30% of all patients who have HCC. Currently, there is no standard therapy for advanced HCC... - Hepatocellular carcinomaJorge A Marrero
University of Michigan, Ann Arbor, 48109, USA
Curr Opin Gastroenterol 22:248-53. 2006..Our aim is to review the latest information regarding the risk factors, markers for early detection, diagnosis, and therapy for this tumor type... - GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinomaJorge A Marrero
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
J Hepatol 43:1007-12. 2005..Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC). The aims of this study were to determine if GP73 is detected in the serum, and to establish the sensitivity and specificity of serum GP73 for diagnosing HCC... - Screening tests for hepatocellular carcinomaJorge A Marrero
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Clin Liver Dis 9:235-51, vi. 2005..The latter point is the main limitation of surveillance for HCC. In this review we will discuss the currently available tests for the surveillance of HCC... - Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohortJorge A Marrero
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
Hepatology 41:707-16. 2005..The BCLC staging system includes aspects of all of these elements and provided the best prognostic stratification for our cohort of patients with HCC... - Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver massJorge A Marrero
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
Liver Transpl 11:281-9. 2005..If additional studies confirm our results, the noninvasive criteria utilized to make a diagnosis of HCC should be revised... - Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patientsJorge A Marrero
Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor 48109, USA
Hepatology 37:1114-21. 2003..810, respectively (P =.002). In conclusion, DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease. Prospective studies to evaluate the role of DCP in early HCC are underway... - Newer markers for hepatocellular carcinomaJorge A Marrero
Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan 48109 0362, USA
Gastroenterology 127:S113-9. 2004..There is an urgent need for novel biomarkers for the detection of early HCC; the National Cancer Institute proposal provides a framework for future validation studies... - Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3Michael L Volk
Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
Cancer Biomark 3:79-87. 2007..In conclusion, DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Serum biomarkers may be less sensitive and specific in the highest risk patients... - Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinomaAmit G Singal
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
J Clin Gastroenterol 45:727-32. 2011..Patient factors associated with surveillance rates are incompletely understood... - Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosisAmit G Singal
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Cancer Epidemiol Biomarkers Prev 21:793-9. 2012..Surveillance for hepatocellular carcinoma (HCC) is recommended in patients with cirrhosis, but the effectiveness of a surveillance program in clinical practice has yet to be established... - Renal outcomes after liver transplantation in the model for end-stage liver disease eraPratima Sharma
Division of Gastroenterology, University of Michigan, Taubman Center, Ann Arbor, MI 48109, USA
Liver Transpl 15:1142-8. 2009..Further studies of modifiable preoperative, perioperative, and postoperative factors influencing renal function are needed to improve outcomes following LT... - Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherencePratima Sharma
University of Michigan Health Systems, Division of Gastroenterology and Department of Pathology, Ann Arbor, MI 48109 0362, USA
Liver Transpl 13:1100-8. 2007..Similar to non-LT patients, those with lower pretreatment HCV RNA, a week 12 virological response, and pegylated IFN and RBV dose adherence were more likely to achieve SVR... - An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network dataShawn J Pelletier
Division of Transplantation, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
Liver Transpl 15:859-68. 2009..The current criteria for liver transplantation of candidates with HCC lead to acceptable 5-year survival while limiting the dropout rate. Liver Transpl 15:859-868, 2009. (c) 2009 AASLD... - Portal vein thrombosis and survival in patients with cirrhosisMichael J Englesbe
Division of Transplantation, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
Liver Transpl 16:83-90. 2010..39; 95% CI, 2.39-22.83). In conclusion, patients with cirrhosis complicated by PVT have an increased risk of death... - Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survivalTheodore H Welling
Departments of Surgery and Medicine, Sections of Transplantation and Hepatology, University of Michigan Health System, MI 48109, USA
Cancer Invest 30:689-97. 2012..15; 95%CI:1.21-3.74) and stage (HR 1.92; 95%CI:1.22-3.97) independently predicted mortality; while viral etiology was protective (HR 0.69; 95%CI:0.41-0.98). Therefore, HCC IL-8 mediated events may be worthy of future investigation... - Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinomaJorge A Marrero
Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
J Hepatol 42:218-24. 2005..The role of tobacco as a risk factor for HCC is controversial. Recently, obesity has been reported to be a risk factor for HCC. We investigated whether these factors increase the risk of HCC in American patients... - Burden of cirrhosis on older Americans and their families: analysis of the health and retirement studyMina O Rakoski
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 5362, USA
Hepatology 55:184-91. 2012..Improved care coordination and caregiver support is necessary to optimize management of this frail population... - MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversiesJonathon M Willatt
Department of Radiology MRI, University of Michigan Health System, UH B2A209K, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0030, USA
Radiology 247:311-30. 2008..MR findings following ablation and chemoembolization are also reviewed... - Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?Amit G Singal
Department of Internal Medicine, UT Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas 75390 8887, USA
Am J Gastroenterol 108:425-32. 2013.... - Who decides? Living donor liver transplantation for advanced hepatocellular carcinomaMichael L Volk
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Transplantation 82:1136-9. 2006.... - Modified Charlson comorbidity index for predicting survival after liver transplantationMichael L Volk
Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
Liver Transpl 13:1515-20. 2007..We demonstrate the usefulness of a modified comorbidity index, the CCI-OLT, for predicting posttransplantation survival... - Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liverAsra S Khan
Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109, USA
J Magn Reson Imaging 32:360-6. 2010.... - Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practiceChanunta Hongthanakorn
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA
Hepatology 53:1854-63. 2011..Counseling of patients with CHB on medication adherence and confirmation of VBT and/or GR can avoid unnecessary changes in antiviral medications... - Failure rates in the hepatocellular carcinoma surveillance processAmit G Singal
Division of Gastroenterology, Dedman Scholar of Clinical Care, University of Texas Southwestern, 5959 Harry Hines Blvd, POB 1, Suite 420, Dallas, TX 75390 8887, USA
Cancer Prev Res (Phila) 5:1124-30. 2012..Future interventions must target multiple failure points in the surveillance process to be highly effective... - A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis CChun-Tao Wai
Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Hepatology 38:518-26. 2003..Application of this index may decrease the need for staging liver biopsy specimens among CHC patients... - Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practiceThomas M Shehab
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
Clin Gastroenterol Hepatol 2:425-31. 2004..In addition, our data show that medication adherence is an important predictor of SVR in an academic clinical practice... - Hepatocellular carcinomaJorge A Marrero
Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109, USA
Curr Opin Gastroenterol 21:308-12. 2005..Standardization of the diagnostic criteria of HCC is critically important for better patient care and future research. Washout of arterially enhancing lesions should be important criteria of HCC... - Early detection of liver cancer: diagnosis and managementMichael L Volk
Division of Gastroenterology and Hepatology, University of Michigan Health System, 3912 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
Curr Gastroenterol Rep 10:60-6. 2008..A new oral agent, sorafenib, was recently shown to prolong survival in patients with advanced HCC. By increasing surveillance and treatment of HCC, outcomes for these patients may be improved... - Role of liver transplantation in the treatment of cholangiocarcinomaAmit Singal
Department of Internal Medicine, University of Michigan, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109, USA
Expert Rev Anticancer Ther 9:491-502. 2009.... - Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle techniqueKatherine E Maturen
Department of Radiology, University of Michigan Hospitals, Ann Arbor, MI 48019 0030, USA
AJR Am J Roentgenol 187:1184-7. 2006..Reported seeding rates range from 0.6% to 5.1% using various biopsy techniques. To our knowledge, the rate of seeding using a coaxial cutting needle technique has not been reported... - Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literatureRyan M Taylor
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA
Liver Transpl 12:781-91. 2006..Corticosteroids and immunoglobulin infusions were effective in 50% while the remainder of patients required rituximab infusions or eventual splenectomy for long-term disease remission... - Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologistsPratima Sharma
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA
Dig Dis Sci 56:569-77. 2011..Our aim was to assess gastroenterologists' knowledge of HCC management guidelines established by the American Association for the Study of Liver Diseases (AASLD) and usual clinical practice... - Recent advances in the treatment of hepatocellular carcinomaAmit G Singal
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Curr Opin Gastroenterol 26:189-95. 2010..Surgical resection, liver transplantation, and local ablative therapies such as radio frequency ablation offer the chance of a cure for tumors detected at an early stage in well selected patients... - Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationScott K Fung
Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA
J Hepatol 43:937-43. 2005..CONCLUSIONS: In conclusion, adefovir resistance can be associated with significant viral rebound and hepatic decompensation which may be fatal... - Recent advances in the treatment of hepatocellular carcinomaKunjali T Padhya
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA
Curr Opin Gastroenterol 29:285-92. 2013..To provide an up-to-date summary of the recent advances in therapies for hepatocellular carcinoma (HCC)... - Diagnosis and treatment of hepatocellular carcinomaHashem B El-Serag
Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas 77030, USA
Gastroenterology 134:1752-63. 2008..In this article, we present a summary of the most recent information on screening, diagnosis, staging, and different treatment modalities of HCC, as well as our recommended management approach... - Liver transplantation for hepatocellular carcinoma: who benefits and who is harmed?Michael Volk
Gastroenterology 134:1612-4. 2008 - Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosisAnand S Mehta
Drexel University College of Medicine and Department of Microbiology and Immunology and Drexel Institute for Biotechnology and Virology, Doylestown, PA 18901, USA
J Virol 82:1259-70. 2008..The reason for the alteration in the glycosylation of anti-Gal IgG is currently unclear but may be related to the natural history of the disease and may be useful in the noninvasive detection of fibrosis and cirrhosis... - Viral hepatitis and hepatocellular carcinomaCarlos Romero Marrero
University of Puerto Rico, San Juan, Puerto Rico
Arch Med Res 38:612-20. 2007..The diagnosis of HCC is established by the presence of an arterially enhancing mass in the presence of cirrhosis. Viral hepatitis represents an opportunity for prevention of HCC... - Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit?Jorge A Marrero
Gastroenterology 126:347-50. 2004 - Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurementsHeping Zhou
The Van Andel Research Institute, 333 Bostwick, Grand Rapids, MI 49503, USA
Genome Biol 5:R28. 2004..Two-color RCA on antibody microarrays should allow the convenient acquisition of expression profiles from a great diversity of proteins for a variety of applications... - SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinomaE Ellen Schwegler
Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
Hepatology 41:634-42. 2005..In conclusion, SELDI-TOF MS serum profiling is able to distinguish HCC from liver disease before cirrhosis as well as cirrhosis, especially in patients with HCV infection compared with other etiologies...
Research Grants
- Complications of Cirrhosis in American PatientsJorge Marrero; Fiscal Year: 2007..I will supervise the conduct of the proposed research and meet with my mentors and advisors regularly. Completing this proposal will allow me to achieve my career goal and to contribute to an improve outcome of patients with HCC. ..
- Early Detection and Prognosis of Patients with Hepatocellular CarcinomaJorge Marrero; Fiscal Year: 2007..Therefore, identifying the risk factors, identifying new methods for early detection and determining prognosis for this tumor is of extreme importance. ..